Glaucoma Clinical Trial
Official title:
Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular
neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion
cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is
known that neuronal cell death in glaucoma occurs by apoptotic mechanism. In earlier
studies, the investigators demonstrated that the process of apoptosis is reflected in
circulating leukocytes by different parameters, like differential messenger ribonucleic acid
(mRNA) expression and an increased fragmentation of the deoxyribonucleic acid (DNA). Such
alterations point out a relationship between cellular stress and apoptotic events.
Based on the results of mRNA-expression, the investigators also expect alterations on the
protein level.
This study is, therefore, designed to characterize the proteome related to the proteins
involved in cell death related pathways.
Thus the expression pattern of several proteins in leukocytes from patients with primary
open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass
spectrometry. These samples will be compared with healthy controls. In addition, they will
be also compared with samples from patients with Parkinson's disease. Since glaucoma is a
neurodegenerative disease, these patients will be included as a positive control in this
study.
Hypothesis:
Subjects with pseudoexfoliation syndrome in combination with glaucoma may have an altered
activity of plasma matrix-metalloproteinase activity and a higher degree of DNA
fragmentation in the leukocytes.
Specific aims:
Determination of the level of plasma matrix-metalloproteinase activity and of the degree of
DNA fragmentation of leukocytes in patients with pseudoexfoliation syndrome glaucoma (PEX)
in comparison to patients with primary open angle glaucoma (POAG).
Background:
One of the main pathogenic factors for the development of glaucoma is an increased
intraocular pressure (IOP), which leads to a direct or indirect damage of the nerve fibers
in the area of the optic disk. The raise of IOP is based on the increased outflow resistance
of the trabecular meshwork due to an excessive accumulation of extracellular material in the
juxtacanalicular tissue of the meshwork in eyes with primary open-angle glaucoma (POAG), and
an impaired turnover of the trabecular meshwork matrix, which is of paramount importance to
the regulation and maintenance of aqueous humor outflow.
Pseudoexfoliation (PEX) syndrome is a systemic disorder of the extracellular matrix, which
represents the most common identifiable cause of open-angle glaucoma. There is increasing
evidence suggesting that PEX syndrome may be a type of fibrosis associated with excessive
synthesis and deposition of an abnormal elastic fibrillar material in many intra- and
extraocular tissues. Active involvement of the trabecular meshwork in this abnormal matrix
process leading to progressive accumulation of PEX material in the juxtacanalicular tissue
is considered to be the primary cause of chronic pressure elevation in eyes with PEX
syndrome. However, the mechanisms responsible for this aberrant matrix process remain
unknown. Excessive production and accumulation of abnormal matrix components may be due to
increased de-novo synthesis, decreased turnover of matrix components, or both.
Extracellular matrix turnover is mediated by matrix metalloproteinases (MMPs), a large
family of endopeptidases with variable substrate spectra, the presence of which has been
described in human aqueous humor.
The activity of these enzymes is regulated in part by specific endogenous inhibitors, the
tissue inhibitors of metalloproteinases (TIMPs). Dysregulated expression of MMPs and TIMPs
has been implicated in many disease processes accompanied by abnormal matrix production,
such as fibrotic disorders, and a variety of other disease states. In the eye, abnormal
expression of MMPs has been implicated, among many other disorders, in glaucoma, in
proliferative vitreoretinopathy, secondary cataract formation, and the pathogenesis of
pterygia. Therefore, MMPs and TIMPs are likely candidates to be involved in the abnormal
extracellular matrix metabolism characteristic of PEX syndrome/glaucoma (PEXG) and POAG.
PEX seems to be an independent risk factor for glaucoma. Possibly, this may be due to an
altered perfusion. So, PEX syndrome represents not only the most common identifiable cause
of open-angle glaucoma, but also a risk factor for cardiovascular diseases. PEX syndrome and
iris trans-illumination defects are seen in patients with transient ischemic attacks. At the
microcirculatory level, ischemia/reperfusion (I/R) injury is thought to be initiated by
chemotactic accumulation of circulating leukocytes, their activation and interaction with
the endothelium of postcapillary venules. In addition, oxygen free radicals are thought to
play a pivotal role in the pathogenesis of I/R injury. A variety of experimental models of
ischemic injury have shown that free radicals induce post-ischemic oxidative damage to DNA.
Although several human studies have revealed that oxygen radicals generated by other
mechanisms like irradiation, only few data exist that demonstrate the influence of
reperfusion-associated oxygen radicals on DNA in humans. We hypothesize that the pathogenic
processes in PEX may be reflected in leukocytes.
Depending on the results that glaucoma patients differ on the level of their mRNA expression
for various MMPs in peripheral leukocytes and that PEX syndrome is often seen with transient
ischemic attacks, we assume differences in the activity of MMPs in the plasma as well as
changes in the DNA stability in peripheral leukocytes of patients with PEX glaucoma.
This study is, therefore, designed to analyze the activity of gelatinases (MMP-2 and -9) in
plasma and the degree of DNA fragmentation in peripheral leukocytes of patients with PEX
syndrome and PEXG compared to POAG and controls.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |